Methotrexate NEW
| Price | $54 | $142 |
| Package | 100mg | 500mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2024-11-05 |
Product Details
| Product Name: Methotrexate | CAS No.: 59-05-2 |
| Purity: 99.46% | Supply Ability: 10g |
| Release date: 2024/11/05 |
Product Introduction
Bioactivity
| 名稱 | Methotrexate |
| 描述 | Methotrexate (WR19039) is a folate analog, an inhibitor of the dihydrofolate reductase DHFR. Methotrexate has antimetabolic, antitumor, and immunosuppressive activities, and is commonly used in rheumatoid arthritis and various tumors. |
| 細(xì)胞實(shí)驗(yàn) | Methotrexate (MTX) is dissolved in DMSO and stored, and then diluted with appropriate media before use[1]. Each cell line is studied in growth inhibition experiments using 96-well microtiter plates. As antifols are schedule dependent, preliminary experiments are aimed at defining the longest duration of exposure that would allow for continuous logarithmic phase growth of cells without changing of the culture media while maintaining a linear relationship between SRB optical density and cell number. Twenty-four hours after cell plating, the cell lines are exposed to the antifol for 120 h (three replicates per experiment). To ensure that a complete sigmoidal survival-concentration curve could be observed, the following drug concentrations are studied: Methotrexate (0.002-5 μM), AMT (0.0001-1 μM), PXD (0.0003-10 μM), TLX (0.0002-0.5 μM). Experiments are repeated at least twice[1]. |
| 體外活性 | METHODS: Six pediatric leukemia and lymphoma cell lines, NALM-6, NALM-16, JURKAT, CEM, RAMOS, and NAMALWA, were treated with Methotrexate (0.002-5 μM) for 120 h, and the proliferation inhibitory activity of the cells was assayed using the SRB method. RESULTS: The median IC50 of Methotrexate against tumor cells was 78 nM, and the IC50 of the six tumor cells ranged from 33-133 nM. [1] METHODS: Human ovarian cancer cells SKOV-3 were treated with Methotrexate (15-50 μM) for 24 h. Apoptosis was detected using AO/EtBr probe. RESULTS: Methotrexate induced apoptosis in SKOV-3 cells. [2] |
| 體內(nèi)活性 | METHODS: To test for chronic toxicity, Methotrexate (0.25-6 mg/kg) was administered intraperitoneally to C57BL/6, DBA/2, and C3H mice five times per week for 12-18 months. RESULTS: The 0.25-2 mg/kg dose was well tolerated with minimal cytostasis in lymphoid tissues, testis and skin. 3-6 mg/kg dose produced well-known acute to subacute hematopoietic and gastrointestinal injuries leading to early death. [3] METHODS: To examine the mode of action in different types of rheumatoid arthritis (RA) and multiple sclerosis (MS) models, Methotrexate (0.1-5 mg/kg) was injected intraperitoneally once a day for fourteen days into RA and MS models with different pathogenesis. RESULTS: Methotrexate showed strong ameliorative effects in classical RA models such as CIA and PIA as well as in MS and EAE models.Methotrexate acts only prior to and dependent on T-cell activation in T-cell activated diseases. [4] |
| 存儲(chǔ)條件 | keep away from direct sunlight | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| 溶解度 | DMSO : 45 mg/mL (99.02 mM) Ethanol : < 1 mg/mL (insoluble or slightly soluble) 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 8.3 mg/mL (18.26 mM), Suspension. Please add co-solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. |
| 關(guān)鍵字 | NCI-C 04671 | WR-19039 | antineoplastic | WR 19039 | DNA/RNA Synthesis | Apoptosis | ADC Cytotoxin | arthritis | rheumatoid | Antifolate | synthesis | ADC Payload | Inhibitor | lymphoblastic | reductase | leukemia | immunosuppressant | Methotrexate | NCI-C-04671 | CL-14377 | inhibit | DNA | CL 14377 |
| 相關(guān)產(chǎn)品 | Stavudine | 5-Fluorouracil | Sodium 4-phenylbutyrate | L-Ascorbic acid | Dextran sulfate sodium salt (MW 4500-5500) | Guanidine hydrochloride | Metronidazole | Tributyrin | Thymidine |
| 相關(guān)庫(kù) | 經(jīng)典已知活性庫(kù) | EMA 上市藥物庫(kù) | 抗癌臨床化合物庫(kù) | 藥物功能重定位化合物庫(kù) | FDA 上市藥物庫(kù) | 抗癌上市藥物庫(kù) | 抗衰老化合物庫(kù) | 已知活性化合物庫(kù) | 抗癌藥物庫(kù) | 抗癌活性化合物庫(kù) |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $142.00/500mg |
VIP3Y
|
TargetMol Chemicals Inc.
|
2024-11-05 | |
| $10.50/1KG |
VIP4Y
|
Hebei Chuanghai Biotechnology Co,.LTD
|
2024-08-20 | |
| $0.00/1g |
VIP1Y
|
BEIJING SJAR TECHNOLOGY DEVELOPMENT CO., LTD.
|
2024-08-05 | |
| $0.00/25kg |
VIP1Y
|
Hebei Mojin Biotechnology Co.,Ltd
|
2024-07-10 | |
| $17.00/1kg |
VIP1Y
|
hebei hongtan Biotechnology Co., Ltd
|
2024-05-16 | |
| $0.00/1kg |
VIP1Y
|
Shaanxi TNJONE Pharmaceutical Co., Ltd
|
2024-04-19 | |
| $50.00/1KG |
VIP1Y
|
Henan Fengda Chemical Co., Ltd
|
2023-12-22 | |
| $15.00/25kg |
VIP5Y
|
Hebei Mojin Biotechnology Co., Ltd
|
2023-08-11 | |
| $10.00/1KG |
VIP6Y
|
Hebei Weibang Biotechnology Co., Ltd
|
2023-03-29 | |
| $1000.00/1kg |
VIP5Y
|
Hebei Yanxi Chemical Co., Ltd.
|
2023-03-23 |
United States- Since: 2011-01-07
- Address: 36?Washington?Street, Wellesley?Hills
INQUIRY